Inserm Research Director
Inserm Unit 894, “Psychiatry and Neurosciences Research Center”
Tel.: +33 (0)1 40 78 86 26
Results of this work are published in Brain.
A cerebrovascular accident (CVA), commonly known as a stroke, corresponds to the blockage or rupture of a vessel carrying blood, and hence oxygen, to the brain. It is an absolute medical emergency, which requires calling the emergency medical services, SAMU (15), or the European emergency number (112) for immediate intervention. Despite the spectacular development in the last 20 years of treatments for restoring blood circulation after acute blockage of a cerebral artery (the commonest form of stroke, known as “ischaemic stroke”), and hence restoring the oxygen supply to the brain as soon as possible after the onset of symptoms, stroke remains a major cause of disability. The most common and disabling sequelae are hemiplegia (paralysis of the left or right side of the body) and aphasia (impairment of spoken or written language, affecting expression and understanding.).
Although the current treatments often succeed in unblocking the vessels and saving the still-viable brain tissues, they cannot save tissues that are already damaged. Moreover, a tissue lacking oxygen, but still viable, becomes rapidly necrotic if blood circulation is not restored urgently. Furthermore, more minor types of stroke, such as transitory ischaemic attacks (TIA), are not indications for these treatments, because the circulation becomes re-established spontaneously, leading to good spontaneous recovery. However, these mini-strokes also cause brain damage. A major objective pursued by physicians and researchers is therefore, in all cases, to protect the still-viable tissue until it can be reperfused and hence reoxygenated.
The mouse model of stroke is considered a good representation of the clinical situation in humans. In this work, the research group led by Jean-Claude Baron tested the hypothesis that normobaric oxygen therapy (100% oxygen delivered by a simple face-mask) prevents the development of brain damage in a model mimicking stroke with early spontaneous reperfusion.
The researchers showed that this very simple treatment almost completely prevents neuronal loss and tissue inflammation in these animals, and completely prevents sensorimotor deficits following brain ischaemia.
For Jean-Claude Baron, Inserm Research Director and neurologist attached to Sainte-Anne Hospital: “This work is also highly valuable for its application to the human situation, as the treatment consists of a simple oxygen bottle and a light facial mask. This treatment would thus be very easy to implement in patients with stroke, as soon as they are being transported by ambulance.
If the clinical value of this easily implemented and inexpensive treatment is later proved by the appropriate randomised trials, it will be possible to both improve the efficacy of treatment and reduce brain damage following TIA/minor stroke, and thereby reduce disability.
 Source: inserm.fr
(Français) En combinant l’utilisation de neurones issus de souris modèles de la maladie de Huntington, une maladie neurologique d’origine génétique, et la technologie microfluidique, l’équipe de Frédéric Saudou, Directeur de Grenoble Institut des Neurosciences (GIN – Inserm/UGA) et responsable de l’équipe « Dynamiques ...
Researchers from Inserm, Sorbonne Université and Université de Bordeaux have published a study based on data from 1,428 children showing that access to a center-based form of childcare between the ages of 0 and 3 years is linked to fewer emotional and ...
Normobaric hyperoxia markedly reduces brain damage and sensorimotor deficits following brief focal ischaemia
Sohail Ejaz, 1,* Julius V. Emmrich, 1, 2,* Sergey L. Sitnikov,1 Young T. Hong,3 Stephen J. Sawiak,3 Tim D. Fryer,3 Franklin I. Aigbirhio,3 David J. Williamson3 and Jean-Claude Baron1,4
1 Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, UK
2 Department of Neurology, Charité – Universitätsmedizin Berlin, Germany
3 Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, UK
4 Inserm U894, Centre Hospitalier Sainte-Anne, Paris Descartes University, Sorbonne Paris Cité, Paris, France
Brain: 15 January 2016